抗PD-1抗体用于儿童难治或复发霍奇金淋巴瘤
回顾性分析北京儿童医院2017年12月至2021年6月接受抗PD-1抗体治疗的6例难治或复发霍奇金淋巴瘤患儿,评估近期与远期疗效及不良反应。用药12周内3例部分反应、3例疾病稳定,16周后5例完全反应、1例部分反应,随访27(21,41)个月5例无事件生存。
要点
- 6例高危难治或复发霍奇金淋巴瘤患儿中,用药16周后5例达完全反应、1例部分反应。
- 治疗期间无一例进展,随访27(21,41)个月5例无事件生存。
- 不良反应可耐受,2例出现反应性皮肤血管增生,停药后自行恢复。
核心结论
- 抗PD-1单克隆抗体用于儿童难治或复发霍奇金淋巴瘤应答较好且不良反应可耐受。
研究设计与样本
- 回顾性病例总结,纳入2017年12月至2021年6月首都医科大学附属北京儿童医院接受PD-1抗体治疗的6例霍奇金淋巴瘤患儿。
- 疗效评估分为完全反应、部分反应、疾病稳定、疾病进展和无反应。
主要发现
- 6例中男5例、女1例,开始PD-1抗体治疗时年龄11.6(10.2,13.3)岁。
- 病理类型为混合细胞型3例、结节硬化型2例、结节淋巴细胞为主型1例;分期Ⅳ期4例、Ⅲ期2例,危险度分组均为高危组,5例存在B组症状。
- 用药12周内早期评估3例部分反应、3例疾病稳定;用药16周后晚期评估5例完全反应、1例部分反应,无一例治疗期间进展。
- 随访时间27(21,41)个月,5例无事件生存并持续缓解;1例停药约4周后发热,后确认为转化为介于弥漫大B细胞和经典霍奇金淋巴瘤的B细胞淋巴瘤。
- 输注期间未见高热、寒战、皮疹等输注反应,无一例因不良反应延迟、减量或停药;2例出现反应性皮肤血管增生,不伴疼痛或痒感,停药后自行恢复。
临床怎么用
- 对儿童难治或复发霍奇金淋巴瘤,可考虑抗PD-1抗体治疗,并在12周与16周左右评估疗效。
- 治疗期间需关注输注反应及皮肤血管增生等不良反应,该组病例均未因不良反应调整用药。
局限性
- 为单中心回顾性病例总结,样本量仅6例,证据强度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the efficacy of anti-programmed cell death protein 1 (PD-1) antibody for children with refractory or relapsed Hodgkin lymphoma. Methods: Clinical data including short-term efficacy, long-term efficacy and adverse reaction of Hodgkin lymphoma children treated with anti-PD-1 antibody in Beijing Children's Hospital, Capital Medical University from December 2017 to June 2021 were analyzed retrospectively. Efficacy was evaluated as complete remission (CR), partial remission (PR), stable disease (SD), progressed disease (PD) and no response. Results: A total of 6 cases were included, including 5 males and 1 female. The age at the start of anti-PD-1 antibody treatment was 11.6 (10.2, 13.3) years, including 3 cases of mixed cellularity type, 2 cases of nodular sclerosis type, and 1 case of nodular lymphocyte-predominant type. There were 4 cases of stage Ⅳ and 2 cases of stage Ⅲ. All cases were assigned to the high-risk group, and 5 cases had B symptoms, all cases were refractory or relapsed Hodgkin lymphoma before the start of anti-PD-1 antibody treatment. Early evaluation showed that within 12 weeks of the treatment, 3 cases achieved PR and 3 cases achieved SD, while late evaluation showed that after 16 weeks of the treatment, 5 cases achieved CR and 1 case achieved PR. None of the children progressed during treatment. The follow-up time was 27 (21,41) months. Among all cases, 5 cases had event-free survival and sustained remission, 1 case had fever about 4 weeks after the drug withdrawal, finally he was confirmed to be transformed to B cell lymphoma between diffuse B cells and classic Hodgkin lymphoma. All the patients were well tolerated with anti-PD-1 antibody therapy. No adverse reactions such as high fever, chills, rash, etc. were observed during infusion. None of the patients were delayed, dose reduction or withdrawal due to adverse reactions. Two cases had reactive skin vascular hyperplasia during the treatment, without pain or itching, and they recovered on their own after stopping anti-PD-1 antibody therapy without other special treatment. Conclusion: Anti-PD-1 monoclonal antibody for children with refractory or relapsed Hodgkin lymphoma have good efficacy and tolerable side effects. 目的: 探索程序性死亡受体1(PD-1)抗体用于儿童难治或复发霍奇金淋巴瘤的治疗反应。 方法: 回顾性病例总结,选择2017年12月至2021年6月就诊于首都医科大学附属北京儿童医院的采用PD-1抗体治疗的6例霍奇金淋巴瘤患儿为研究对象。收集患儿的临床资料,评估近期、远期随访疗效及不良反应。疗效评估分为完全反应、部分反应、疾病稳定、疾病进展和无反应。 结果: 6例患儿中男5例、女1例,开始PD-1抗体治疗时年龄为11.6(10.2,13.3)岁。病理类型为混合细胞型3例、结节硬化型2例、结节淋巴细胞为主型1例。分期Ⅳ期4例、Ⅲ期2例;危险度分组均为高危组,5例患儿存在B组症状,所有患儿在开始PD-1治疗前状态均为难治或复发。PD-1抗体首次用药后12周内早期评估3例部分反应、3例疾病稳定,用药16周后晚期评估5例完全反应、1例部分反应,无一例患儿治疗期间出现进展。随访时间27(21,41)个月,5例患儿无事件生存,持续缓解状态,1例患儿停药4周后发热,后确认为转化为介于弥漫大B细胞和经典霍奇金淋巴瘤的B细胞淋巴瘤。6例患儿用药耐受性较好,输注期间未见高热、寒战、皮疹等输注反应,无一例患儿因不良反应延迟、减量或停药。2例在治疗过程中出现反应性皮肤血管增生,不伴疼痛或痒感,未给予特殊处理,停药后自行恢复。 结论: PD-1抗体用于难治或复发霍奇金淋巴瘤患儿治疗应答较好且不良反应可耐受。.
引用
- Li Y, Duan YL, Huang M, et al. [Application of anti-programmed cell death protein 1 antibody in children with refractory or relapsed Hodgkin lymphoma]. Zhonghua Er Ke Za Zhi. 2022. PMID: 35658365. doi:10.3760/cma.j.cn112140-20211014-00869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。